Genetic Polymorphisms and Antiplatelet Drug Individualized Treatment

Abstract

Abstract:

Platelet activation and aggregation play a crucial role in the pathophysiology of atherothrombosis. Aspirin and clopidogrel have become common drugs in treating and preventing ischemic stroke by inhibiting platelet activation and aggregation. There is a great difference of antiplatelet drugs' inhibition effects on platelet aggregation in individual patients. Resistance on anti-platelet drugs could increase risk of stroke relapse. The exact mechanism of variable response to antiplatelet drugs is still unclear. Multiple potential mechanisms have been proposed. In this article, we will discuss the genetic polymorphisms and antiplatelet drug resisitance, in order to guide individualized treatment.

Key words: Aspirin; Clopidogrel; Resistance; Genetic polymorphisms

摘要：

血小板的活化与聚集在血栓形成的病理生理中起着重要的作用，而抗血小板治疗是动脉硬化性脑梗死急性期治疗、一级及二级预防的重要组成部分。目前阿司匹林、氯吡格雷为最常用的抗血小板药物。但抗血小板药物对不同人群血小板抑制作用存在较大差异，人群对抗血小板药物的低反应性与缺血性脑血管病复发具有相关性，本篇将重点从基因多态性的角度阐述抗血小板药物抵抗的可能机制，指导临床个体化治疗。

关键词: 阿司匹林; 氯吡格雷; 抵抗; 基因多态性

SHAO Yuan*,DING Hong, XU Yun.. Genetic Polymorphisms and Antiplatelet Drug Individualized Treatment[J]. Chinese Journal of Stroke, 2014, 9(04): 309-316.

邵渊1，丁红2，徐运1. 基因多态性与抗血小板药物个体化治疗研究[J]. 中国卒中杂志, 2014, 9(04): 309-316.

References

1 陈竺. 中华人民共和国卫生部全国第三次死因回顾

抽样调查报告[M]. 北京:中国协和医科大学出版社,

2008:10-17.

2 王文志. 中国脑血管病防治研究现状和发展方向[J]. 中

国现代神经疾病杂志, 2011, 11:134-137.

3 中华医学会神经病学分会脑血管病学组急性缺血性脑

卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指

南2010[J]. 中华神经科杂志, 2010, 43:146-153.

4 Kaplan ZS, Jackson SP, Hematology AM, et al. The

role of platelets in atherothrombosis[J]. Hematology

Am Soc Hematol Educ Program, 2011, 1:51-61.

5 Haeke W, Kaste M, Bluhmki E, et al. Thrombolysis

with alteplase 3 to 4.5 hours after acute ischemic

stroke[J]. N Engl J Med, 2008, 359:1317-1329.

6 中华医学会神经病学分会脑血管病学组缺血性脑卒

中二级预防指南撰写组. 中国缺血性脑卒中和短暂性

脑缺血发作二级预防指南2010[J]. 中华神经科杂志,

2010, 43:154-160.

7 Fitzgerald R, Pirmohamed M. Aspirin resistance:effect

of clinical, biochemical and genetic factors[J].

Pharmacol Ther, 2011, 130:213-225.

8 Buonamici P, Marcucci R, Migliorini A, et al. Impact

of platelet reactivity after clopidogrel administration

on drug-eluting stent thrombosis[J]. J Am Coll Cardiol,

2007, 49:2312-2317.

9 Go r e l i ck PB, Fa r o o q MU. Ad va n c e s i n ou r

understanding of "resistance" to antiplatelet agents

for prevention of ischemic stroke[J]. Stroke Res Treat,

2013, 2013:727842.

10 Vane JR. Inhibition of prostaglandin synthesis as a

mechanism of aspirin-like Drugs[J]. Nat New Biol,

197l, 231:232-235.

11 Weber AA, Przytulski B, Schanz A, et al. Towards

a def inition of aspirin resistance:a typological

approach[J]. Platelets, 2002, 13:37-40.

12 Patrono C, Coller B, Dalen JE. The relationship among

dose, effectiveness, and side effects[J]. Chest, 2001,

119:39S-63S.

13 Simon T, Verstuyf t C, Mar y-Krause M, et al.

Genetic determinants of response to clopidogral and

cardiovascular events[J]. N Engl J Med, 2009, 360:363-

375.

14 Sharma V, Kaul S, Al-Hazzani A, et al. Association of

C3435T multi drug resistance gene-1 polymorphism

with aspirin resistance in ischemic stroke and its

subtypes[J]. J Neurol Sci, 2012, 315:72-76.

15 Russel FG, Koenderink JB, Masereeuw R. Multidrug

resistance protein 4 (MRP4/ABCC4):a versatile efflux

transporter for drugs and signalling molecules[J].

Trends Pharmacol Sci, 2008, 29:200-207.

16 Schuetz JD, Connelly MC, Sun D, et al. MRP4:A

previously unidentif ied factor in resistance to

nucleoside-based antiviral drugs[J]. Nat Med, 1999,

5:1048-1051.

17 Mattiello T, Guerriero R, Lotti LV, et al. Aspirin

extrusion from human platelets through multidrug

resistance protein-4-mediated transport:evidence of a

reduced drug action in patients after coronary artery

bypass grafting[J]. J Am Coll Cardiol, 2011, 58:752-761.

18 Ansari M, Sauty G, Labuda M, et al. Polymorphisms

in multidrug resistance-associated protein gene

4 is associated with outcome in childhood acute

lymphoblastic leukemia[J]. Blood, 2009, 114:1383-1386.

19 Fitzgerald DJ, Maree A. Aspirin and clopidogrel

resistance[J]. Hematology Am Soc Hematol Educ

Program, 2007:114-120.

20 Wang LH, Hajibeigi A, Xu XM, et al. Characterization

of the promoter of human prostaglandin H synthase-1

gene[J].Biochem Biophys Res Commun, 1993,

190:406-411.

21 Maree AO, Curtin RJ, Chubb A, et al. Cyclooxygenase-1

haplotype modulates platelet response to aspirin[J]. J

Thromb Haemost, 2005, 3:2340-2345.

22 Ag nd e z JA, Ma r t ne z C, P r e z -Sa l a D, e t a l .

Pharmacogenomics in aspirin intolerance[J]. Curr Drug

Metab, 2009, 10:998-1008.

23 Li Q, Chen BL, Ozdemir V, et al. Frequency of genetic

polymorphisms of COX-1, GPIIIa and P2Y1 in a

Chinese population and association with attenuated

response to aspirin[J]. Pharmacogenomics, 2007, 8:577-

586.

24 Shi J, Misso N L, Duffy D L, et al. Cyclooxygenase-1

gene polymorphisms in patients with different asthma

phenotypes and atopy[J]. Eur Respir J, 2005, 26:249-

256.

25 李晓利, 曹剑, 范利, 等. 中国老年心脑血管疾病患者阿

司匹林抵抗与环氧化酶-1单体型关联分析[J]. 中国应

用生理学杂志, 2012, 28:225-229.

26 Caughey GE, Cleland LG, Penglis PS, et al. Roles of

cyclooxygenase (COX)-1 and COX-2 in prostanoid

production by human endothelial cells:selective upregulation

of prostacyclin synthesis by COX-2[J]. J

Immunol, 2001, 167:2831-2838.

27 Papaf ili A, Hill MR, Brull DJ, et al. Common

promoter variant in cyclooxygenase-2 represses

gene expression:evidence of role in acute-phase

inflammatory response[J]. Arterioscler Thromb Vasc

Biol, 2002, 22:1631-1636.

28 Sharma V, Kaul S, Al-Hazzani A, et al. Association of

COX-2 rs20417 with aspirin resistance[J]. J Thromb

Thrombolysis, 2013, 35:95-99.

29 王毅盟, 倪培华, 杨蓉, 等. 环氧化酶-2启动子区基因单

核苷酸多态性与老年人阿司匹林抵抗的关系[J]. 上海

交通大学学报(医学版), 2012, 32:301-306.

30 Unoki M, Furuta S, Onouchi Y et al. Association

studies of 33 single nucleotide polymorphisms (SNPs)

in 29 candidate genes for bronchial asthma:positive

association a T924C polymorphismin the thromboxane

A2 receptor gene[J]. Hum Genet, 2000, 106:440-446.

31 Fujiwara T, Ikeda M, Esumi K, et al. Exploratory

aspirin resistance trial in healthy Japanese volunteers

(J-ART) using platelet aggregation as a measure of

thrombogenicity[J]. Pharmacogenomics, 2007, 7:395-

403.

32 Gao F, Wang ZX, Men JL, et al. Effect of polymorphism

and type II diabetes on aspirin resistance in patients

with unstable coronary artery disease[J]. Chin Med J

(Engl), 2011, 124:1731-1734.

33 Herrera-Galeano JE, Becker DM, Wilson AF, et al. A

novel variant in the platelet endothelial aggregation

receptor-1 gene is associated with increased platelet

aggregability[J]. Arterioscler Thromb Vasc Biol, 2008,

28:1484-1490.

34 Kunicki TJ, Nugent DJ. The genetics of normal platelet

reactivity[J]. Blood, 2010, 116:2627-2634.

35 Lewis JP, Ryan K, O'Connell JR. Genetic variation

in PEAR1 is associated with platelet aggregation and

cardiovascular outcomes[J]. Circ Cardiovasc Genet,

2013, 6:184-192.

36 吴涛, 姜瑞民, 苏颖. 血小板膜糖蛋白研究进展[J]. 北

京医学, 2011, 33:701-703.

37 Pamukcu B, Oflaz H, Nisanci Y. The role of platelet

glycoprotein IIIa polymorphism in the high prevalence

of in vit ro aspir in resistance in patients with

intracoronary stent restenosis[J]. Am Heart J, 2005,

149:675-680.

38 Goodman T, Ferro A, Sharma P. Pharmacogenetics

of aspirin resistance:a comprehensive systematic

review[J]. Br J Clin Pharmacol, 2008, 66:222-232.

39 茅新蕾, 颜雪琴, 韩丽雅, 等. 阿司匹林抵抗与GPⅢa基

因多态性的相关性研究[J]. 现代实用医学, 2011, 23:18-

21.

40 Yonal I, Hindilerden F, Hancer VS, et al. The impact

of platelet membrane glycoprotein Ib alpha and Ia/

IIa polymorphisms on the risk of thrombosis in the

antiphospholipid syndrome[J]. Thromb Res, 2012,

129:486-491.

41 苏冠华, 王朝晖, 丁艳萍, 等. 血小板膜糖蛋白I a 807C/

T多态性与阿司匹林抵抗的关系[J]. 中国血液流变学

杂志, 2007, 17:43-45.

42 Ma r t e a u F, Le Po u l E , Commu n i D, e t a l .

Pharmacological characterization of the human P2Y13

receptor[J]. Mol Pharmacol, 2003, 64:104-112.

43 Savi P, Zachayus JL, Delesque-Touchard N, et al.

The active metabolite of Clopidogrel disrupts P2Y12

receptor oligomers and partitions them out of lipid

rafts[J]. Proc Natl Acad Sci USA, 2006, 103:11069-

11074.

44 Feher G, Feher A, Pusch G, et al. The genetics of

antiplatelet drug resistance[J]. Clin Genet, 2009, 75:1-

18.

45 Topçuoglu MA, Arsava EM, Ay H. Antiplatelet

resistance in stroke[J]. Expert Rev Neurother, 2011,

11:251-263.

46 Ma TK, Lam YY, Tan VP, et al. Impact of genetic and

acquired alteration in cytochrome P450 system on

pharmacologic and clinical response to clopidogrel[J].

Pharmacol Ther, 2010, 125:249-259.

47 Hol lopet e r G, Jant zen HM, Vincent D, et al.

Identification of the platelet ADP receptor targeted by

antithrombotic drugs[J]. Nature, 2001, 409:202-207.

48 Rai M, Seip RL, Gupta A , et al. CYP2C19 genotypeguided

antiplatelet therapy in a patient with clopidogrel

resistance[J]. Conn Med, 2012, 76:267-272.

49 Fontana P, Dupont A, Gandrille S, et al. Adenosine

diphosphate-induced platelet aggregation is associated

with P2Y12 gene sequence variations in healthy

subjects[J]. Circulation, 2003, 108:989-995.

50 Fontana P, Gaussem P, Aiach M, et al. P2Y12 H2

haplotype is associated with peripheral arterial

disease:a case-control study[J]. Circulation, 2003,

108:2971-3973.

51 von Beckerath N, von Beckerath O, Koch W, et al.

P2Y12 gene H2 haplotype is not associated with

increased adenosine diphosphate-induced platelet

aggregation after initiation of clopidogrel therapy with

a high loading dose[J]. Blood Coagul Fibrinolysis,

2005, 16:199-204.

52 Gurbel PA, Bliden KP. Durability of platelet inhibition

by clopidogrel[J]. Am J Cardiol, 2003, 91:1123-1125.

53 Price MJ, Berger PB, Teirstein PS, et al. Standardvs

high-dose clopidogrel based on platelet function

testing after percutaneous coronary intervention:the

GRAVITAS randomized t r ial[J]. JAMA, 2011,

305:1097-1105.

54 Hashimoto H, Toide K, Kitamura R, et al. Gene

structure of CYP3A4, an adult-specific form of

cytochrome P450 in human livers, and its transcriptional

control[J]. Eur J Biochem, 1993, 218:585-595.

55 Angiollo DJ, Fernandez-Ortiz A, Bernardo E, et

al. Contribution of gene sequence variations of the

hepatic cyto-chrome P450 3A4 enzyme to variability in

individual responsiveness to clopidogrel[J]. Arterioscler

Thromb Vasc Bio, 2006, 26:1895-1900.

56 韩雅玲, 麦晓燕, 李毅, 等. 细胞色素P450 3A4 894C>T

位点基因多态性与氯吡格雷抵抗的关系[J]. 解放军医

学杂志, 2008, 33:939-942.

57 Fontana P, Hulot JS, Moerloose P, et al. Influence

of CYP2C19 and CYP3A4 gene polymorphism on

clopidogrel responsiveness in healthy subjects[J]. J

Thromb Haemost, 2007, 5:2153-2155.

58 Kit zmi l le r J P, Groen DK, Phelps MA, e t a l.

Pharmacogenomic testing:Relevance in medical

practice:Why drugs work in some patients but not in

others[J]. Cleve Clin J Med, 2011, 78:243-257.

59 Coutts RT, Urichuk LJ. Polymorphic cytochromes P450

and drugs used in psychiatry[J]. Cell Mol Neurobiol,

1999, 19:325-354.

60 Rai M, Seip RL, Gupta A, et al. CYP2C19 genotypeguided

antiplatelet therapy in a patient with clopidogrel

resistance[J]. Conn Med, 2012, 76:267-272.

61 Varenhorst C, James S, Erlinge D, et al. Genetic

variation of CYP2C19 affects both pharmacokinetic

and pharmacodynamic responses to clopidogrel but

not prasugrel in aspirin-treated patients with coronary

artery disease[J]. Eur Heart J, 2009, 30:1744-1752.

62 Suh JW, Koo BK, Zhang SY, et al. Increased risk of

atherothrombotic events associated with cytochrome

P450 3A5 p olymor ph i sm i n pa t ie nt s t a k i ng

clopidogrel[J]. CMAJ, 2006, 174:1715-1722.

63 Jia DM, Chen ZB, Zhang MJ, et al. CYP2C19

polymorphisms and antiplatelet effects of clopidogrel

in acute ischemic stroke in China[J]. Stroke, 2013,

44:1717-1719.

[1]	ZHENG Jianhua, CUI Yanling, CAO Ying, DAI Jianwu. A Case Report of Capsule Warning Syndrome Treated with Tirofiban Bridging Dual Antiplatelet Therapy after Intravenous Thrombolysis with Alteplase [J]. Chinese Journal of Stroke, 2024, 19(3): 326-330.
[2]	HOU Yuting, LI Tong. A Case Report of Dual Antiplatelet Therapy for Acute Basilar Artery Occlusion Based on Rapid CYP2C19 Gene Detection [J]. Chinese Journal of Stroke, 2024, 19(10): 1125-1130.
[3]	ZHANG Taihui, REN Hong. A Case Report of Dual Antiplatelet Therapy for Severe Stenosis of the Internal Carotid Artery Based on Rapid CYP2C19 Gene Detection [J]. Chinese Journal of Stroke, 2024, 19(10): 1131-1134.
[4]	WANG Mengxing, PAN Yuesong, LIU Dandan, JIN Aoming. Considerations for Clinical Trial Negative Results [J]. Chinese Journal of Stroke, 2023, 18(06): 645-650.
[5]	LIU Jianwei, ZHEN Yong, SONG Bingwei, CHENG Jiao, GENG Ping, HU Jianbing. Etiology and Antibacterial Drug Resistance Analysis of Post-microsurgery Pneumonia in Patients with Poor-grade Aneurysmal Subarachnoid Hemorrhage [J]. Chinese Journal of Stroke, 2023, 18(01): 83-89.
[6]	XU Zhichao, LI Runzhi, MI Donghua. Relationship between Central Insulin Resistance and Cerebrovascular Disease [J]. Chinese Journal of Stroke, 2022, 17(11): 1276-1282.
[7]	WEN Shaohong, LIU Xiangrong, ZHAO Shunying, DONG Wen, CHEN Qingfang, CHEN Wentao, LI Zixiao, WANG Chunjuan. Effects of Aspirin Combined with Clopidogrel on the Expression of RAGE and sRAGE during the Convalescence of Cerebral Ischemia in Mice [J]. Chinese Journal of Stroke, 2022, 17(08): 821-828.
[8]	FU Conghui, CHEN Mei, LI Xiaotong, XIAO Qinqin, HU Kang, KONG Fangcao, WEI Jinye, JIA Jie. Effects of Resistance Training on Respiratory Function, Exercise Endurance and Negative Emotion in Stroke Patients at Chronic Stage [J]. Chinese Journal of Stroke, 2022, 17(06): 573-578.
[9]	DONG Wen, JIANG Mingyu, CHEN Wentao, LIU Wenqian, CHEN Qingfang, ZHAO Shunying, YE Weizhen, WEN Shaohong, LIU Xiangrong. The Effect of Dual Antiplatelet Therapy with Aspirin and Clopidogrel on Inflammatory Response in Bone Marrow and Brain after Cerebral Ischemia Injury in Mice [J]. Chinese Journal of Stroke, 2022, 17(06): 605-610.
[10]	LI Zhenhua, LIU Zhu, HU Quanzhong. Progress in Drugs Therapy for Non-disabling Ischemic Cerebrovascular Events [J]. Chinese Journal of Stroke, 2022, 17(04): 407-412.
[11]	HUANG Yan, FU Xuejun, SHI Huijie, ZOU Liangyu. Correlation between Triglyceride-Glucose Index and Neurological Function Impairment after Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2022, 17(03): 251-257.
[12]	WANG Cong-Jie, LI Hong, ZHENG Li, LIU Shan, LU Hai-Li, CHEN Na, ZHANG Bin, ZHOU Heng. Efficacy of Dual Antiplatelet Therapy after Intravenous Thrombolysis in Patients with Mild Ischemic Stroke [J]. Chinese Journal of Stroke, 2021, 16(10): 1044-1049.
[13]	YU Feng-Chun, QI Yan-Yan, ZHANG Jing, GAO Bing, WANG Xue-Hong, ZHAO Feng-Li, WANG Su-Li, FANG Zhi-Yong, QIAO Shu-Dong, BI Qi. Safety and Efficacy of 50 mg Enteric Sustained-Release Aspirin Tablet in Secondary Prevention of Mild Ischemic#br# Stroke/Transient Ischemic Attack#br# [J]. Chinese Journal of Stroke, 2021, 16(07): 657-663.
[14]	CHENG Yue, SHAO Teng-Fei, HUANG Li-Li, YANG Dan, XU Yun. Platelet Function Test in Predicting the Efficacy and Safety of Clopidogrel Secondary Prevention of Ischemic Stroke#br# [J]. Chinese Journal of Stroke, 2021, 16(06): 574-580.
[15]	PAN Yue-Song, J. Donald Easton, LI Hao, Anthony S. Kim, MENG Xia,S. Claiborne Johnston, JIN Ao-Ming, WANG Yong-Jun. Effect of Clopidogrel plus Aspirin Therapy on Functional Outcome in Minor Stroke or Transient Ischemic Attack:Pooled Analysis of CHANCE and POINT [J]. Chinese Journal of Stroke, 2021, 16(02): 157-162.